Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Other Non Operating Income (2019 - 2025)

BridgeBio Pharma's Other Non Operating Income history spans 7 years, with the latest figure at -$21.2 million for Q1 2025.

  • For Q1 2025, Other Non Operating Income rose 20.44% year-over-year to -$21.2 million; the TTM value through Dec 2025 reached -$21.2 million, up 20.44%, while the annual FY2025 figure was -$21.2 million, 20.44% up from the prior year.
  • Other Non Operating Income for Q1 2025 was -$21.2 million at BridgeBio Pharma, up from -$37.2 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $35.4 million in Q2 2024 and bottomed at -$37.2 million in Q4 2024.
  • The 5-year median for Other Non Operating Income is $1.5 million (2023), against an average of -$794800.0.
  • The largest annual shift saw Other Non Operating Income plummeted 7700.0% in 2021 before it soared 2301.15% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $28.3 million in 2021, then tumbled by 57.36% to $12.1 million in 2022, then crashed by 112.24% to -$1.5 million in 2023, then tumbled by 2422.9% to -$37.2 million in 2024, then skyrocketed by 43.19% to -$21.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Other Non Operating Income are -$21.2 million (Q1 2025), -$37.2 million (Q4 2024), and $1.8 million (Q3 2024).